Status: Recruiting
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.
Participants needed: 95
Trial details
Phase: Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: Oorja Bio, Inc.Updated: Oct 9, 2026Locations: 1
Eligibility criteria
Male or female participants aged ≥ 40 years when signing informed consent [+5]
Participants who are treatment-naïve with respect to SOC antifibrotic therapies [+7]